What Are the Clinical Implications of the Phase III IMerge Trial?

Amer Zeidan, MBBS, MHS, of Yale University, discusses results of the phase III IMerge trial, which he presented during the 2023 American Society of Clinical Oncology Annual Meeting.

The randomized, double-blind, placebo-controlled study evaluated imetelstat in patients with heavily transfusion dependent non-del(5q) lower-risk myelodysplastic syndromes who relapsed or were refractory to erythropoiesis stimulating agents.

In this video, Dr. Zeidan speaks about the rationale behind the trial, the implications of its results, and the next steps now that the phase III trial has met its primary endpoint.